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Prion disorders belong to the group of neurodegenerative diseases involving 
protein misfolding. Prion protein (PrP) aggregation and neurotoxicity are 
believed to result from the accumulation of infectious PrP (PrPSc), a particular 
misfolded form of the normal PrP (PrPC). The biochemical features of PrPSc 
are resistance to proteinase K (PK) digestion and detergent insolubility. The 
physiological roles of PrPC are yet to be defined; however, some studies have 
shown that PrPC may be involved in metal ion homeostasis. In diseased brains, 
iron levels are increased, which is possible because of the coaggregation of 
PrP with ferritin. Although iron is known to be involved in the generation of 
abnormal PrP, little is known about the contribution of oxidation state-
ii 
 
dependent iron to PrP conversion and the conversion mechanism in neural 
cells. In this study, murine PrPC-deficient cells (HpL3-4) were exposed to 
divalent [Fe (II)] or trivalent [Fe (III)] iron and then treated with exogenous 
recombinant PrP (rPrP). After the internalization of rPrP by the cells, we 
analyzed the accumulation of intracellular rPrP and its biochemical properties 
in combination with PK resistance and detergent insolubility. U18666A and 
NH4Cl were used to inhibit vesicular trafficking and endolysosomal 
acidification, respectively. We found that Fe (III) induced an increase of 
internalized rPrP in a time- and dose-dependent manner. Moreover, the 
accumulated rPrP was converted to detergent-insoluble and PK-resistant PrP 
(PrPres) in part. The generation of PrPres was hindered by U18666A, but not by 
NH4Cl, indicating that Fe (III)-mediated PrP
res conversion possibly occurred 
during endosomal vesicular trafficking and not in the acidic environment of 
lysosomes. These results suggest that Fe (III), and not Fe (II), has a role in the 
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Fatal neurodegenerative prion disorders occur in many vertebrates 
including human, cattle, and small ruminants. These disorders belong to the 
family of protein misfolding diseases including Alzheimer’s disease, 
Huntington’s disease, and Parkinson’s disease. The central event in all prion 
disorders is the conversion of PrP to a beta-sheet rich form (PrP scrapie; 
PrPSc) from an alpha-helix rich form of PrP (cellular PrP; PrPC). The 
generation of PrPSc has been observed in exogenous prion sources, including 
scrapie in sheep, bovine spongiform encephalopathy in cattle, chronic 
wasting disease in deer and elk; it has also been observed to result from the 
pathological mutations in the gene for PrP, or from stochastic misfolding of 
PrPC in sporadic Creutzfeldt-Jacob disease (Collinge, 2001). Resistance to 
limited proteolysis and detergent insolubility are biochemical features of the 
abnormal PrP distinguished from the normal PrP. 
  Even though PrP aggregation and neurotoxicity are believed to result from 
the accumulation of PrPSc, these main pathologies might be caused not only 
by PrPSc but also by other elements or factors of prion pathogenesis (Das et 
al., 2010; Zhou et al., 2012). In diseased brains, imbalance in brain metal 
homeostasis and associated oxidative stress have been observed (Singh et al., 
2010; Rana et al., 2009; Fernaeus and Land, 2005). Proposed hypotheses 
include a functional role of PrPC in homeostasis of iron and copper, and loss 




probably causing an imbalance of metals in the brain. Other views suggest 
that PrPSc acquires a toxic function due to sequestration of PrPC-associated 
metals within the aggregates, resulting in the generation of redox-active 
PrPSc complexes (Singh et al., 2009; Pauly and Harris, 1998; Brown et al. 
2000). In support of these hypotheses, iron content is observed to increase in 
the cerebral cortex, striatum, and brain stem of scrapie-infected mice (Singh 
et al., 2009; Kim et al., 2007); however, copper content is observed to 
decrease (Thackray et al., 2002). Increased iron induces oxidative stress-
associated neurotoxicity and aggravated impairment of antioxidant activities 
in prion-infected cells and animals (Fernaeus, 2005; Wong, 2001). Recently, 
several investigations have addressed the relationship between redox-iron 
and PrP (Kim et al., 2000; Singh et al., 2009). Iron overload induced the 
aggregation of PrPC and rendered PrP resistant to proteinase K (PK) 
digestion (Basu et al., 2007; Singh et al., 2009). Moreover, neurotoxicity 
associated with aggregates of PrP and iron has been studied in PrPC over-
expressing neuroblastoma cells (Das et al., 2010; Basu et al., 2007; Singh et 
al., 2009). However, the relative contribution of the 2 oxidative states of iron, 
divalent [Fe (II)] or trivalent [Fe (III)], in the generation of abnormal PrP 
isoforms has not been investigated. In addition, mechanisms for iron-
mediated PrP transformation remain to be determined. 
Establishment of an experimental cell model in which prion conversion 
takes place in the absence of interference of endogenous PrPC would provide 
a tractable system for evaluating PrP alteration processes. Even though 




formation, the cell biology of prion conversion and its cellular effect(s) are 
not fully understood. Approaches using cell-free conditions have attempted 
to study factors associated with PrP aggregation and PK resistance (Jackson 
et al., 1999; Martins et al., 2006; Qin et al., 2000), but by their nature lack 
biological context. Cell lines that are susceptible to prion infection have been 
used to delineate the conversion processes but are limited because PrPSc is 
immunologically indistinguishable from PrPC (Alais et al., 2008; 
Marijanovic et al., 2009). Moreover, cytotoxic effects specifically associated 
with the intracellular accumulation of abnormal isoforms are poorly defined 
due to the additional effects caused by the loss of PrPC normal function 
(Westergard et al., 2007; Das et al., 2010). Therefore, an experimental cell 
model that induces intracellular PrP conversion without interference from 
endogenous PrPC would be useful to understand the conversion process and 
to evaluate the cytotoxic effect of converted PrP. 
In this study, cells devoid of endogenous PrPC were overloaded with iron 
and treated with recombinant bovine prion protein (rPrP). We exploited iron 
to induce intracellular PrP conversion over copper because of its 
pathological implications in prion diseases. From our results, Fe (III), but not 
Fe (II), induced an accumulation of internalized rPrP and converted PrP to a 
PK-resistant form (PrPres). Reactive oxygen species (ROS) were partly 
involved in the generation of Fe (III)-mediated PrPres; however, our data 
suggest additional endogenous factors remain to be identified. Moreover, 
endosomal trafficking and not the acidic environment of lysosomes appears 








  The PrP-deficient HpL3-4 cell line (Kuwahara et al. 1999) was kindly 
provided by Prof. Yong-Sun Kim (Hallym University, South Korea) under 
the permission of Prof. Takashi Onodera (University of Tokyo, Japan). The 
neuronal cell line was maintained in complete medium, the high glucose 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-
inactivated fetal bovine serum (FBS) at 37°C with 5% CO2. DMEM and 
FBS were purchased from Invitrogen Life Technologies (Grand Island, NY, 
USA) and Hyclone (Logan, UT, USA), respectively. Mouse anti-prion 
protein monoclonal antibody against amino acid 108-119 in prion, 1E4, was 
purchased from Abcam (Cambridge, UK). Rabbit anti-lamin A/C 
monoclonal antibody was obtained from Santa Cruz Biotechnology (Santa 
Cruz, C.A, USA), and anti-β-actin was obtained from Cell Signaling 
Technology (Beverly, MA, USA). For HRP-conjugated secondary antibodies, 
anti-mouse IgG antibody was obtained from Cell Signaling Technology 
(Beverly, MA, USA), anti-goat IgG antibody was purchased from Santa 
Cruz Biotechnology (Santa Cruz, C.A, USA), and anti-rabbit IgG was from 
Sigma (Sigma-Aldrich, MO, USA). Protease K was purchased from 
Invitrogen Life Technologies (Grand Island, NY, USA). U18666A from 




the manufacturer’s instructions. The BCA protein assay kit was purchased 
from Pierce Chemical (Rockford. IL, USA). Unless indicated otherwise, all 
the chemicals including ferrous chloride (FeCl2) and ferric ammonium 
citrate (FAC) were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA). 
 
Generation of recombinant proteins  
 
  rPrP cloned in a pET23 vector (Novagen, Madison, WI, USA) was 
expressed in Escherichia coli BL21 (DE3) after induction with isopropyl-β-
D-thiogalactopyranoside (IPTG, 1 mM) for 14 h. The cells were re-
suspended in cold PBS with 5 mM ethylenediaminetetraacetic acid (EDTA) 
and protease inhibitor cocktail and then sonicated. Inclusion bodies were 
collected by centrifugation at 100,000 × g for 30 min and solubilized with 
buffer A (20 mM sodium phosphate, pH 7.4; 6 M guanidine hydrochloride 
[GdnHCl]; 20 mM imidazole; 0.5 M NaCl). After brief sonication, the 
solubilized proteins were collected by centrifugation at 100,000 × g for 30 
min. Cleared lysates were loaded onto HiTrap Chelating HP column (GE 
Healthcare, WI, USA), and rPrP was eluted using buffer B (20 mM sodium 
phosphate, pH 7.4, 6 M GdnHCl, 0.5 M imidazole, 0.5 M NaCl). Fractions 
were dialyzed against 50 mM sodium acetate, pH 5.0, containing 5% 
glycerol and then re-dialyzed against 20 mM HEPES at pH 7.4.  




(Novagen, Madison, WI, USA) was expressed in E. coli BL21 (DE3) after 
induction with 1 mM IPTG for 6 h. The cells were lysed by performing 
sonication, and the lysates were clarified at 80,000 × g for 20 min at 4°C. 
rGal-3 was purified from the lysates by performing affinity chromatography 
with asialofetuin-Sepharose 4B and washed with 100 mM sodium phosphate, 
pH 7.2, containing 150 mM NaCl followed by PBS containing 2 mM 
dithiothreitol (DTT). Competitive elution was performed with 0.4 M lactose 
in PBS containing 2 mM DTT. The eluted proteins were dialyzed against 
PBS and redialyzed against 20 mM HEPES at pH 7.4. 
 
Treatment of cells with iron and rPrP 
 
 The cells were plated with a density at 0.4 × 105 cells/mL. After 4 h of 
stabilization, the cells were exposed to either 0.3 mM FeCl2 designated as Fe 
(II) or 0.6 mM FAC as Fe (III) for 24 h. Then 0.6 μM rPrP (about 25 μg/mL) 
were added to the media and incubated for another 24 h. Mock-exposed cells 
treated with rPrP were used as the control. For analyzing the effects of other 
trivalent metal ion exposures, 0.6 mM aluminum chloride [Al (III)] and 
chromium chloride [Cr (III)] were used. To assess ROS involvement in the 
generation of PrPres, dimethyl sulfoxide (DMSO) at the indicated 
concentrations was added to the cells 30 min prior to iron exposure, and then 
rPrP treatment was performed. In an attempt to assess the intracellular 
conversion process, U18666A and ammonium chloride (NH4Cl) were used. 




Cells exposed to Fe (II) or Fe (III) were subsequently treated with the drug. 
After 24 h of incubation, rPrP was added and incubated for a further 24 h. 
For NH4Cl treatment, 20 mM NH4Cl was added 30 min prior to the rPrP 
treatment. To analyze changes in the level of PrPres, cell lysates were either 
treated with PK at 5 μg/mL and subjected to immunoblotting or were left 
untreated.  
 
Whole cell lysates preparation 
 
After trypsinization, the cells were washed with PBS 3 times to exclude 
contamination with rPrP from media. The collected cells were lysed in buffer 
A (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.25% sodium 
dodecyl sulfate (SDS), 2% NP-40, 1% sodium deoxycholate, protease 
inhibitor cocktail, PMSF) for 30 min at 4°C. After a brief centrifugation, the 
supernatant was collected, and total protein concentration was measured 
using the BCA protein assay kit.  
 
Proteinase K treatment 
 
After metal exposure and rPrP treatment, the PBS-washed cells were lysed 
in buffer A without protease inhibitors. Digestion was performed by treating 
the protein of each sample (1 mg/mL) with 5 μg/mL concentration of PK at 





Detergent insolubility   
 
After washing with PBS, the cells were collected in lysis buffer A, and 
large debris were removed by centrifugation at 350 × g for 5 min. 
Supernatants were subjected to centrifugation at 16,000 × g for 45 min. 
Protein concentration was measured by performing the BCA protein assay. 
Samples of the insoluble fraction from re-suspended pellets and of the 
soluble fraction from supernatants were prepared. 
 
Assessment of cytotoxicity 
 
Cytotoxicity was determined using the WST-8 assay using the Cell 
Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Kumamoto, 
Japan). Cells were exposed to FeCl2 or FAC at various concentrations, and 
then incubated with 10 μL of WST-8 for another 4 h. The absorbance was 





Sample proteins subjected to 15% sodium dodesyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) were transferred onto polyvinylidene 
difluoride (PVDF) membranes (Millipore; Immobilon-P membranes). The 




room temperature. Membranes were probed overnight by using the primary 
anti-PrP antibody 1E4, anti-galectin-3 antibody m3/38 (purified in our 
laboratory), anti-lamin A/C antibody, or β–actin antibody, followed by 
treatment with appropriate secondary antibodies. The blots were developed 
by using enhanced chemiluminescence (GE Healthcare, Waukesha, WI, 
USA). Relative intensity of the proteins was analyzed using ImageJ analysis 




  All the experiments were repeated at least 3 times. The results are 
expressed as mean +/- STDV. Statistical analysis was performed by Tukey’s 
test for comparing multiple groups using the SPSS software (SPSS, Chicago, 













                     II. RESULTS 
 
Cytotoxicity of iron in HpL3-4 cells 
 
Iron exposure to HpL3-4 cells exhibited marginal cytotoxicity. The 
cytotoxicity of the 2 states of iron over a range of concentrations (0.3-2.4 
mM for FeCl2 and FAC) was examined to select an optimal concentration of 
metal exposure for investigating metal-mediated intracellular conversion of 
PrP. Perturbations of various metals including iron and copper have been 
observed in prion diseases. Iron was chosen for the study due to its high 
redox-active property and physiological interaction with PrP (Pauly and 
Harris, 1998; Brown and Harris, 2003; Singh et al., 2009) but also increases 
of the 2 transitional states of iron as well as total iron in prion disease-
affected human and animal brains (Singh et al., 2009; Kim et al., 2000). For 
iron exposure, 0.3 mM FeCl2 is an optimal concentration for generation of 
PrPSc-like aggregates in endogenous PrPC-overexpressing human 
neuroblastoma cells (PrPC cells) (Basu et al., 2007). This treatment simulates 
in vivo conditions of oxidative stress, for which an active fragment of 
protein kinase C (PKC) δ is considered to be a positive biomarker (Kaul et 
al., 2003). The cytotoxicity of 0.3 mM FeCl2 exposure in HpL3-4 cells for 
48 h produced less than 5% reduction in cell viability, unlike that observed 
in the control (Fig. 1). The cytotoxicity of FAC showed no significant 




always lower than that observed with FeCl2 at the same concentrations. 
 
Accumulation of internalized rPrP after Fe (III) 
exposure 
To investigate the effect of the 2 states of iron on intracellular PrP 
accumulation and conversion to a PrPSc-like isoform, exogenous rPrP was 
added to the cells after metal exposure. Preliminary experiments confirmed 
that the treatment of histidine-tagged rPrP at 0.6 μM did not affect cell 
viability (data not shown). Cells were exposed to FeCl2 or FAC over a range 
of concentrations from 0.3 to 1.2 mM. After 24 h of iron exposure, 0.6 μM 
rPrP was additionally added to the media, and the cells were incubated for 
another 24 h. The level of internalized rPrP from whole cell lysates was 
detected using 1E4 antibody, which recognizes amino acids 108-119 of 
bovine PrP including the N-terminal part of the PK-resistant PrP27-30 
fragment. The levels of internalized rPrP were proportional to the iron 
concentration (Fig. 2). Interestingly, the amount of rPrP from the Fe (III)-
exposed cells was considerably higher than the Fe (II)-exposed cells. Fe (III) 
dramatically induced a 13-fold increase in the level of rPrP, unlike that 
observed in the mock-exposed control (Fig. 3-A, lane 5, and Fig. 3-B); 
however, cells with Fe (II) exposure displayed a marginal increase compared 
to the controls (Fig. 3-A, lane 4, and Fig. 3-B). No signals were detected 
from the cells without rPrP treatment (Fig. 3-A, lane 2), demonstrating a 




  Incubation of cells with rPrP for 4, 8, 16, and 24 h showed that the 
accumulation was time-dependent. In the cells exposed to Fe (III), the level 
of rPrP increased over time (Fig. 4). It was low at early timepoints during the 
incubation (4 h, lane 9), but increased dramatically at later times (8, 16 and 
24 h, lane 10–12). Although cells exposed to Fe (II) displayed an increase in 
rPrP until 16 h of incubation, the increase was marginal and eventually 
returned to the control levels (lane 5–8). 
  It was uncertain whether the increase in rPrP was specific to Fe (III) or 
whether any trivalent cation would elicit a similar effect. To determine this, 
cells were exposed to other trivalent metal ions including Al (III) and Cr (III). 
However, neither Al (III) nor Cr (III) exposure induced the accumulation of 
rPrP (Fig. 5). 
 To verify whether the Fe (III)-mediated increase in rPrP was specific to that 
particular protein, or was a general phenomenon applicable to other 
exogenous proteins, we treated cells with 0.6 μM of rGal-3, which has a 
similar molecular weight (29 kDa) to rPrP. The level of internalized rGal-3 
in Fe (III)-exposed cells was similar to that in the control cells (Fig. 6). 
Endogenous galectin-3 in HpL3-4 cells had a slightly higher molecular 
weight (ca.30 kDa) (Henderson, 2006) and was expressed at comparable 
levels in the control and Fe (III)-exposed cells. 
 





A detergent solubility assay is commonly used to distinguish PrPSc-like 
characteristics from PrPC. To examine the solubility of internalized rPrP, 
cells were lysed in a buffer containing the ionic denaturant SDS at a 
concentration of 0.25%. Equal amounts of the proteins were fractionated into 
soluble and insoluble compartments, and rPrP from each fraction was 
detected. rPrP was present mainly in the insoluble fraction, while lamin A/C, 
a nuclear membrane protein, was found in the soluble fraction regardless of 
metal exposure (Fig. 7). Endogenous PrPC is known to be soluble (Thellung 
et al., 2011), whereas internalized rPrP was observed to be insoluble. 
 
Intracellular conversion to PrPres with Fe (III) 
 
Resistance to PK treatment is considered a hallmark of PrPC-to-PrPSc 
conversion. To assess whether internalized rPrP subjected to iron exposure 
showed PrPSc-like characteristics, resistance against PK digestion was 
analyzed (Fig 8). Cells were treated with lysis buffer without protease 
inhibitors and then incubated with PK (0, 1, 5, 10 μg/mL). rPrP from Fe 
(III)-exposed cells displayed partial PK resistance, designated as PrPres (Fig. 
8, lane 9–12). Upon increasing concentrations of PK, intact rPrP (25 kDa) 
underwent digestion and generated a PK-resistant fragment (16 kDa). On the 
contrary, rPrP from the control and Fe (II)-exposed cells was completely 
degraded at a minimal concentration of 1 μg/mL. To define whether a direct 
reaction between rPrP and Fe (III) might have induced PrPres formation, 0.6 




(Fig. 9). Immunoblots revealed that this simple reaction failed to render rPrP 
resistance against PK digestion. These data indicate that Fe (III)-mediated 
conversion to PrPres occurs in a complex cellular milieu. 
 
Involvement of ROS in the generation of PrPres with Fe 
(III) 
 
Since iron is a known to be a redox-active metal ion, and iron-associated 
oxidative stress has been implicated in prion pathologies (Milhavet et al., 
2000; Petersen et al., 2005), the effect of DMSO on the formation of PrPres 
was examined. DMSO is a ROS scavenger and reduces hydrogen peroxide-
induced intracellular ROS production (Watt et al., 2005). When the cells 
were incubated with DMSO (0.5 and 1 %), there was a dose-dependent 
reduction of PrPres (Fig. 10). 
 
Fe (III)-mediated conversion in vesicular trafficking 
 
To examine an intracellular process in which PrPres was formed, we used 
U18666A, which is known to effectively inhibit vesicular trafficking from 
early endosomes (EE) to late endosomes (LE), LE to lysosomes (LY), and 
LY to plasma membrane or endoplasmic reticular, by the induction of 
cholesterol accumulation in LE and LY. These effects of U18666A ultimately 
prevent protein degradation (Cenedella, 2009; Mayran et al., 2003; 




after the cells had been exposed to iron. Under the drug treatment, PrPres 
disappeared, although the high level of rPrP were still detected in the Fe 
(III)-exposed cells (Fig. 11). Next, the involvement of the acidic 
environment of LY in the formation of PrPres was examined using NH4Cl. 
This compound is an inhibitor of endolysosomal acidification and impairs 
the lysosomal degradation system (Misinzo, 2008). Iron-exposed cells were 
pretreated with 20 mM of NH4Cl before rPrP addition. Endolysosomal 
acidification inhibition had a negligible effect on the reduction of PrPres (Fig. 
12). Noticeably, following impairment of the lysosomal degradation system, 
high levels of rPrP in both control and Fe (II)-exposed cells were observed; 





                    IV. DISCUSSION 
 
In this study, internalized rPrP was converted into PrPres by Fe (III) during 
vesicular trafficking in the cells devoid of endogenous PrPC. The 
accumulation and conversion of rPrP was specifically induced by Fe (III) but 
not by Fe (II), despite previous assumptions that both cations participated 
equally in prion diseases (Fig. 3 and 8). Notably, the discrepancy in the level 
of intracellular rPrP was due to the acquisition of resistance to cellular 
degradation, rather than to a differential cellular uptake of rPrP. Moreover, 
other trivalent metal ions such as Al (III) and Cr (III) failed to induce rPrP 
accumulation, and other exogenous protein such as rGal-3 did not 
accumulate after by Fe (III) treatment (Fig. 5 and 6); these data indicate a 
specific reaction between Fe (III) and rPrP.  
From previous studies involving prion-infected cells and brains (Singh et 
al., 2009; Fernaeus and Land, 2005; Petersen et al., 2005), iron has been 
implicated in prion pathology; however, the level of contribution of each 
oxidation state of iron to prion conversion has not been fully investigated. 
Studies of Singh and colleagues reported that FeCl2 and FAC induced a prion 
conformational change into detergent-insoluble and/or PK-resistant isoforms 
when exposed to cells that overexpress endogenous PrPC (Das et al., 2010; 
Basu et al., 2007). These observations were interpreted as the formation of 
ferritin-PrP coaggregates, which confers both PrP resistance to PK digestion 




Das et al., 2010). However, ferritin upregulation and the formation of PrP 
coaggregates occurred regardless of iron’s cationic valence states (Das et al., 
2010; Basu et al., 2007). Therefore, their explanation does not seem to 
account for the different outcomes we observed between Fe (II) and Fe (III) 
in this study. The discrepancies may be explained in at least 2 ways. First, 
there are distinctive molecular mechanisms of intracellular iron transport 
depending on iron’s oxidative state: vesicular and nonvesicular iron import 
[30]. Cellular uptake of Fe (III) occurs via receptor-mediated endocytosis of 
transferrin (Tf). The Fe (III)-Tf complex then binds to a specific membrane-
bound transferring receptor. Uptake of Fe (II), on the other hand, is mediated 
by plasma membrane-localized iron importers such as DMT1 and TRPML1. 
Vesicular transport of rPrP and Fe (III) might provide a favorable 
environment for PrP conversion. Second, Fe (II) and Fe (III) may have 
different binding affinities for rPrP. The affinity of PrP for iron is still 
unknown. Although limited to in vitro experiments with rPrP, Fe (III), and 
not Fe (II), was able to bind to rPrP (Brown et al., 2000; Basu et al., 2007). It 
is interesting to note that conversion of normal PrP to PrPSc-like 
characteristics is rPrP-specific, and not a general phenomenon, as shown 
here by the negligible changes in internalized rGal-3 levels regardless of Fe 
(III) exposure (Fig. 6). However, we cannot exclude the possibility that other 
neurodegenerative disease-associated proteins might also be affected by Fe 
(III).  
The mechanism of conversion from rPrP to PrPres remains unclear. 




(III)-mediated PrPres conversion was induced not due to a direct contact 
between Fe (III) and rPrP, and instead requires a complex cellular milieu 
(Fig. 9). Moreover, we find that ROS is an auxiliary factor that participates 
in PrP conversion. Through the Fenton reaction, redox-active metals 
including iron and copper can promote generation of ROS, such as the 
hydroxyl radical derived from hydrogen peroxide (White et al., 1999). The 
involvement of ROS in the formation of PrPres was supported by the 
inhibitory effect of DMSO in our experiments (Fig. 10). Redox-active iron in 
the vicinity of rPrP might increase the possibility of attack at sites in the 
proteins by generating free radicals, potentiating the PrP conversion process. 
However, the partial inhibitory effect of DMSO suggests that not only ROS 
but also other cellular factor(s) participate in the Fe (III)-mediated 
intracellular conversion. 
Assessment of PK resistance after treatment with U18666A or NH4Cl 
demonstrated that vesicular trafficking, and not acidic lysosomes is a 
relevant process/site where Fe (III)-associated PrP conversion occurred (Fig. 
11 and 12). If conversion to PrPres was because of the acidic environment in 
the lysosomes, under acidification inhibition, it would have been sensitive to 
PK treatment. This notion simply excludes the involvement of acidic 
lysosomes in the generation of Fe (III)-mediated PrPres. Noticeably, 
reduction of PrPres with U18666A indicated blockage of PrPres formation. 
This suggests that endosomal trafficking may play a role in PrPres formation. 
Since endocytosed and intracellular components within vesicles dynamically 




pathway leading to lysosomes (van der Goot and Gruenberg, 2006), a 
factor(s) present in vesicles might be required for the rPrP to obtain PK 
resistance. The observations that cholesterol depletion reduced PrPSc levels 
have underscored the importance of a lipid environment for PrP conversion 
(Bate et al., 2004; Mange et al., 2000). This phenomenon has been explained 
by the perturbation of PrPC to associate with lipid rafts (Taraboulos et al., 
1995), membrane microdomains characterized by a high content of 
sphingolipids and cholesterol, and the reduction of cell surface expression of 
PrPC (Gilch et al., 2006). Although U18666A, which inhibits cholesterol 
recycling, has also been shown to impair PrPSc propagation, it did not affect 
the interaction between PrPC and lipid rafts (Marijanovic et al., 2009; Gilch 
et al., 2009). Moreover, the HpL3-4 cell line is PrPC-deficient, and therefore, 
the cell surface expression of PrPC is required for neither U18666A-
mediated PrPres reduction nor Fe (III)-associated PrPres generation in this 
experimental condition.  
 A limitation of this study is that cells were exposed to excessive amounts of 
iron compared to the levels found in diseased brains or other iron-overloaded 
cell models (Das et al., 2010; Basu et al., 2007). Despite the artificial 
condition, PrPres in our experimental cell model exhibited PrPSc-like features 
including partial PK resistance and detergent insolubility; this presumably 
corresponds to the recombinant PrPres that was converted by PrPSc in terms 
of biochemical properties and molecular size (Atarashi et al., 2008; Eiden et 
al., 2006). The cellular model shows similar phenomenon seen in PrPSc-




U18666A on the generation of PrPres (Goold et al., 2011), and maintenance of 
PK resistance following inhibition of lysosomal acidification (Marijanovic et 
al., 2009). Therefore, this experimental system can be a useful tool to study 
intracellular mechanism of PrP conversion, to evaluate potential drugs with 
anti-prion activity, and for assessment of the neurotoxic effects of PrP 
isoforms. Iron dyshomeostasis has been observed not only in prion-infected 
brains and animal models but also in sporadic prion disease (Singh et al., 
2009; Caughey and Baron, 2006). Furthermore, not only normal aging brain 
but also brains with other neurodegenerative diseases, including Alzheimer’s 
and Parkinson’s (Mills et al., 2010), have shown abnormal iron accumulation. 
Therefore, this cell model can provide insight into the potential roles of iron 




















Figure 1. Cytotoxicity of iron in PrPC deficient HpL3-4 cells. 
Cell viability was assessed by CCK-8. Cells were exposed to FeCl2 and FAC 
with various concentrations, and then incubated with 10 μL of WST-8 for 
another 4 h. The absorbance was measured at 450 nm, and the results are 













   
Figure 2. Concentration-dependent accumulation of internalized rPrP with Fe 
(III). The cells were exposed 0.3 to 1.2 mM FeCl2 or FAC for 24 h. Then 0.6 
μM rPrP was added and incubated for another 24 h. Equal amounts of cell 
lysate were resolved by performing SDS-PAGE and were immunoblotted. 



















Figure 3. Accumulation of internalized rPrP with Fe (III). 
(A) Immunoblotting of internalized rPrP from mock- (lane 3), Fe (II)- (lane 4), 
or Fe (III)-(lane 5) exposed cell lysates with 1E4. No signal was detected from 
the cell lysates without rPrP treatment (lane 2). Purified rPrP (200 ng, lane 1) 
was loaded to compare the electrophoretic run of intact and fragmented PrP 
before and after intracellular uptake. (B) Quantification of internalized rPrP 
showed a dramatic increase (above 13-fold) in the level of rPrP from the cells 
exposed to Fe (III), unlike that observed in the control (Con). Levels of rPrP 
from each lysate were normalized to lamin A/C. Values are represented as 
percentage of rPrP level with iron exposures (mean +/-STDV) with respect to 
the control. Statistical significance between the experimental groups and 


















Figure 4. Time-dependent accumulation of internalized rPrP with Fe (III) 
exposure. Detection of rPrP from cells treated with rPrP for 4 (lane 1, 5, and 
9), 8 (lane 2, 6, and 10), 16 (lane 3, 7, and 11), or 24 h (lane 4, 8, and 12) 


















    
Figure 5. Fe (III)-specific accumulation of rPrP. The cells were exposed to 
other trivalent metal ions, Al (III) and Cr (III), as well as Fe (II) and Fe (III). 
Al (III) or Cr (III) did not induce an increase in the level of rPrP in the cells 
















Figure 6. rPrP-specific accumulation with Fe (III). Immunoblotting of rGal-
3 from the cells that were exposed to mock (lane 3) or Fe (III) (lane 4) for 24 
h and then treated with 0.6 μM rGal-3 for another 24 h. Endogenous 
galectin-3 (white arrow) was detected from cells without rGal-3 treatment 
(lane 2). Purified rGal-3 (50 ng) was loaded to distinguish the internalized 










Figure 7. Insoluble rPrP in a detergent containing SDS. The cells were 
exposed to iron for 24 h and additionally treated with rPrP (0.6 μM) for 
another 24 h. Collected cells were lysed in 0.25 % SDS containing lysis 
buffer, cleared of debris, and pelleted. Supernatants (lane 1–3) and pellet 










Figure 8. Conversion from rPrP to PrPres with Fe (III). The cells exposed to 
iron for 24 h were treated with rPrP (0.6 μM) for another 24 h. Proteins from 
each cell lysate (1 mg/mL) were treated with PK (1, 5, and 10 μg/mL) for 30 
min at 37°C. From the cells exposed to Fe (III), both intact (25 kDa) and 
fragment (16 kDa) were detected at 5 μg/mL PK, indicating that internalized 
rPrP acquired partial PK resistance (lane 11). At 10 μg/mL of PK, the 
majority of PrP were degraded but a weak signal from the PK-resistant 
fragment was detected (lane 12). On the contrary, rPrP from cells exposed to 
Fe (II) (lane 5–8) were completely degraded by PK at 1 μg/mL, which was 












Figure 9. Failure to generate PrPres in a cell free reaction. Iron and rPrP (0.6 
μM in 20 mM HEPES, pH7.4) were allowed to react under cell-free 
conditions in vitro. rPrP exposed to mock, Fe (II), or Fe (III) at 37°C for 24 h 


















Figure 10. Partial involvement of ROS in the generation of PrPres. Levels of 
rPrP (PK-) and PrPres (PK+) after DMSO treatment were analyzed by 
immunoblotting. DMSO, a ROS scavenger, was added to cells 30 min prior 
to Fe (III) exposure. After 24 h incubation, 0.6 μM rPrP were then added to 
media for another 24 h. The collected cells in the lysis buffer without 














Figure 11. Inhibition of PrPres generation by U18666A. Levels of rPrP (PK-) 
and PrPres (PK+) after U18666A treatment were analyzed by immunoblotting. 
Cells exposed to mock, Fe (II), or Fe (III) were treated with (+) or without (-) 
3 μM U18666A for 24 h (A). Then 0.6 μM rPrP was treated with the media 
for another 24 h. The lysates were incubated with PK at 5 μg/mL (PK+) or 
were left untreated (PK-). Following U18666A treatment, the formation of 
















Figure 12. No effect of NH4Cl on PrP
res generation. Levels of rPrP (PK-) 
and PrPres (PK+) after NH4Cl treatment were analyzed by immunoblotting. 
Cells exposed to mock, Fe (II), or Fe (III) were treated with (+) or without 
20 mM NH4Cl. Then 0.6 μM rPrP was added to the media for another 24 h. 
Lysates were incubated with PK at 5 μg/mL (PK+) or were left untreated 
















Alais, S., S. Simoes, D. Baas, S. Lehmann, G. Raposo, J. L. Darlix, and P. Leblanc. 
2008. Mouse neuroblastoma cells release prion infectivity associated with 
exosomal vesicles. Biol Cell 100 (10):603-15. 
Atarashi, R., J. M. Wilham, L. Christensen, A. G. Hughson, R. A. Moore, L. M. 
Johnson, H. A. Onwubiko, S. A. Priola, and B. Caughey. 2008. Simplified 
ultrasensitive prion detection by recombinant PrP conversion with shaking. 
Nat Methods 5 (3):211-2. 
Basu, S., M. L. Mohan, X. Luo, B. Kundu, Q. Kong, and N. Singh. 2007. 
Modulation of proteinase K-resistant prion protein in cells and infectious 
brain homogenate by redox iron: implications for prion replication and 
disease pathogenesis. Mol Biol Cell 18 (9):3302-12. 
Bate, C., M. Salmona, L. Diomede, and A. Williams. 2004. Squalestatin cures prion-
infected neurons and protects against prion neurotoxicity. J Biol Chem 279 
(15):14983-90. 
Brown, D. R., F. Hafiz, L. L. Glasssmith, B. S. Wong, I. M. Jones, C. Clive, and S. J. 
Haswell. 2000. Consequences of manganese replacement of copper for 
prion protein function and proteinase resistance. EMBO J 19 (6):1180-6. 
Brown, L. R., and D. A. Harris. 2003. Copper and zinc cause delivery of the prion 
protein from the plasma membrane to a subset of early endosomes and the 
Golgi. J Neurochem 87 (2):353-63. 
Caughey, B., and G. S. Baron. 2006. Prions and their partners in crime. Nature 443 
(7113):803-10. 
Cenedella, R. J. 2009. Cholesterol synthesis inhibitor U18666A and the role of sterol 
metabolism and trafficking in numerous pathophysiological processes. 
Lipids 44 (6):477-87. 
Collinge, J. 2001. Prion diseases of humans and animals: their causes and molecular 




Das, D., X. Luo, A. Singh, Y. Gu, S. Ghosh, C. K. Mukhopadhyay, S. G. Chen, M. S. 
Sy, Q. Kong, and N. Singh. 2010. Paradoxical role of prion protein 
aggregates in redox-iron induced toxicity. PLoS One 5 (7):e11420. 
Eiden, M., G. J. Palm, W. Hinrichs, U. Matthey, R. Zahn, and M. H. Groschup. 2006. 
Synergistic and strain-specific effects of bovine spongiform 
encephalopathy and scrapie prions in the cell-free conversion of 
recombinant prion protein. J Gen Virol 87 (Pt 12):3753-61. 
Fernaeus, S., and T. Land. 2005. Increased iron-induced oxidative stress and toxicity 
in scrapie-infected neuroblastoma cells. Neurosci Lett 382 (3):217-20. 
Gilch, S., C. Bach, G. Lutzny, I. Vorberg, and H. M. Schatzl. 2009. Inhibition of 
cholesterol recycling impairs cellular PrP(Sc) propagation. Cell Mol Life 
Sci 66 (24):3979-91. 
Gilch, S., C. Kehler, and H. M. Schatzl. 2006. The prion protein requires cholesterol 
for cell surface localization. Mol Cell Neurosci 31 (2):346-53. 
Goold, R., S. Rabbanian, L. Sutton, R. Andre, P. Arora, J. Moonga, A. R. Clarke, G. 
Schiavo, P. Jat, J. Collinge, and S. J. Tabrizi. 2011. Rapid cell-surface prion 
protein conversion revealed using a novel cell system. Nat Commun 2:281. 
Jackson, G. S., L. L. Hosszu, A. Power, A. F. Hill, J. Kenney, H. Saibil, C. J. Craven, 
J. P. Waltho, A. R. Clarke, and J. Collinge. 1999. Reversible conversion of 
monomeric human prion protein between native and fibrilogenic 
conformations. Science 283 (5409):1935-7. 
Kaul, S., A. Kanthasamy, M. Kitazawa, V. Anantharam, and A. G. Kanthasamy. 2003. 
Caspase-3 dependent proteolytic activation of protein kinase C delta 
mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced 
apoptotic cell death in dopaminergic cells: relevance to oxidative stress in 
dopaminergic degeneration. Eur J Neurosci 18 (6):1387-401. 
Kim, B. H., Y. C. Jun, J. K. Jin, J. I. Kim, N. H. Kim, E. A. Leibold, J. R. Connor, E. 
K. Choi, R. I. Carp, and Y. S. Kim. 2007. Alteration of iron regulatory 
proteins (IRP1 and IRP2) and ferritin in the brains of scrapie-infected mice. 




Kim, N. H., S. J. Park, J. K. Jin, M. S. Kwon, E. K. Choi, R. I. Carp, and Y. S. Kim. 
2000. Increased ferric iron content and iron-induced oxidative stress in the 
brains of scrapie-infected mice. Brain Res 884 (1--2):98-103. 
Kobayashi, T., M. H. Beuchat, M. Lindsay, S. Frias, R. D. Palmiter, H. Sakuraba, R. 
G. Parton, and J. Gruenberg. 1999. Late endosomal membranes rich in 
lysobisphosphatidic acid regulate cholesterol transport. Nat Cell Biol 1 
(2):113-8. 
Kuwahara, C., A. M. Takeuchi, T. Nishimura, K. Haraguchi, A. Kubosaki, Y. 
Matsumoto, K. Saeki, T. Yokoyama, S. Itohara, and T. Onodera. 1999. 
Prions prevent neuronal cell-line death. Nature 400 (6741):225-6. 
Mange, A., N. Nishida, O. Milhavet, H. E. McMahon, D. Casanova, and S. Lehmann. 
2000. Amphotericin B inhibits the generation of the scrapie isoform of the 
prion protein in infected cultures. J Virol 74 (7):3135-40. 
Marijanovic, Z., A. Caputo, V. Campana, and C. Zurzolo. 2009. Identification of an 
intracellular site of prion conversion. PLoS Pathog 5 (5):e1000426. 
Martins, S. M., D. J. Frosoni, A. M. Martinez, F. G. De Felice, and S. T. Ferreira. 
2006. Formation of soluble oligomers and amyloid fibrils with physical 
properties of the scrapie isoform of the prion protein from the C-terminal 
domain of recombinant murine prion protein mPrP-(121-231). J Biol Chem 
281 (36):26121-8. 
Mayran, N., R. G. Parton, and J. Gruenberg. 2003. Annexin II regulates 
multivesicular endosome biogenesis in the degradation pathway of animal 
cells. EMBO J 22 (13):3242-53. 
Milhavet, O., H. E. McMahon, W. Rachidi, N. Nishida, S. Katamine, A. Mange, M. 
Arlotto, D. Casanova, J. Riondel, A. Favier, and S. Lehmann. 2000. Prion 
infection impairs the cellular response to oxidative stress. Proc Natl Acad 
Sci U S A 97 (25):13937-42. 
Mills, E., X. P. Dong, F. Wang, and H. Xu. 2010. Mechanisms of brain iron transport: 





Pauly, P. C., and D. A. Harris. 1998. Copper stimulates endocytosis of the prion 
protein. J Biol Chem 273 (50):33107-10. 
Petersen, R. B., S. L. Siedlak, H. G. Lee, Y. S. Kim, A. Nunomura, F. Tagliavini, B. 
Ghetti, P. Cras, P. I. Moreira, R. J. Castellani, M. Guentchev, H. Budka, J. 
W. Ironside, P. Gambetti, M. A. Smith, and G. Perry. 2005. Redox metals 
and oxidative abnormalities in human prion diseases. Acta Neuropathol 110 
(3):232-8. 
Qin, K., D. S. Yang, Y. Yang, M. A. Chishti, L. J. Meng, H. A. Kretzschmar, C. M. 
Yip, P. E. Fraser, and D. Westaway. 2000. Copper(II)-induced 
conformational changes and protease resistance in recombinant and cellular 
PrP. Effect of protein age and deamidation. J Biol Chem 275 (25):19121-31. 
Rana, A., D. Gnaneswari, S. Bansal, and B. Kundu. 2009. Prion metal interaction: is 
prion pathogenesis a cause or a consequence of metal imbalance? Chem 
Biol Interact 181 (3):282-91. 
Singh, A., A. O. Isaac, X. Luo, M. L. Mohan, M. L. Cohen, F. Chen, Q. Kong, J. 
Bartz, and N. Singh. 2009. Abnormal brain iron homeostasis in human and 
animal prion disorders. PLoS Pathog 5 (3):e1000336. 
Singh, A., M. L. Mohan, A. O. Isaac, X. Luo, J. Petrak, D. Vyoral, and N. Singh. 
2009. Prion protein modulates cellular iron uptake: a novel function with 
implications for prion disease pathogenesis. PLoS One 4 (2):e4468. 
Singh, N., D. Das, A. Singh, and M. L. Mohan. 2009. Prion Protein and Metal 
Interaction: Physiological and Pathological Implications. Curr Issues Mol 
Biol 12 (2):99-108. 
Singh, N., A. Singh, D. Das, and M. L. Mohan. 2010. Redox control of prion and 
disease pathogenesis. Antioxid Redox Signal 12 (11):1271-94. 
Taraboulos, A., M. Scott, A. Semenov, D. Avrahami, L. Laszlo, and S. B. Prusiner. 
1995. Cholesterol depletion and modification of COOH-terminal targeting 
sequence of the prion protein inhibit formation of the scrapie isoform. J 
Cell Biol 129 (1):121-32. 




Metal imbalance and compromised antioxidant function are early changes 
in prion disease. Biochem J 362 (Pt 1):253-8. 
Thellung, S., A. Corsaro, V. Villa, A. Simi, S. Vella, A. Pagano, and T. Florio. 2011. 
Human PrP90-231-induced cell death is associated with intracellular 
accumulation of insoluble and protease-resistant macroaggregates and 
lysosomal dysfunction. Cell Death Dis 2:e138. 
van der Goot, F. G., and J. Gruenberg. 2006. Intra-endosomal membrane traffic. 
Trends Cell Biol 16 (10):514-21. 
Watt, N. T., D. R. Taylor, A. Gillott, D. A. Thomas, W. S. Perera, and N. M. Hooper. 
2005. Reactive oxygen species-mediated beta-cleavage of the prion protein 
in the cellular response to oxidative stress. J Biol Chem 280 (43):35914-21. 
Westergard, L., H. M. Christensen, and D. A. Harris. 2007. The cellular prion 
protein (PrP(C)): its physiological function and role in disease. Biochim 
Biophys Acta 1772 (6):629-44. 
White, A. R., S. J. Collins, F. Maher, M. F. Jobling, L. R. Stewart, J. M. Thyer, K. 
Beyreuther, C. L. Masters, and R. Cappai. 1999. Prion protein-deficient 
neurons reveal lower glutathione reductase activity and increased 
susceptibility to hydrogen peroxide toxicity. Am J Pathol 155 (5):1723-30. 
Zhou, M., G. Ottenberg, G. F. Sferrazza, and C. I. Lasmezas. 2012. Highly 
neurotoxic monomeric alpha-helical prion protein. Proc Natl Acad Sci U S 













 프리온 질병은 단백질 변성에 기인하는 퇴행성 뇌질병 중의 
하나이다. 이 질병의 주요 현상인 프리온 단백질의 응집과 신경 
독성은 전염성을 지닌 병원성 단백질의 축적에 의한 결과라고 
생각되어 지고 있다. 하지만 병원성 프리온 이외에 다른 요인들도 
프리온 변성에 영향을 줄 수 있음이 제기된 바 있다. 정상 프리온 
단백질의 생리적인 기능은 명확히 밝혀지진 않았지만 금속 이온의 
항상성 조절에 관여함이 보고되어 있다. 특히, 프리온 질병에서 철 
이온의 증가가 관찰되는데 이는 프리온 단백질이 철 저장체와 
응집을 이루기 때문으로 여겨진다. 철 이온이 변성 프리온 생성에 
관련되어 있음이 보고되어 있다. 이 학위논문에서는 이온가에 따른 
철이 프리온 변성에 어떠한 영향을 미치는지와 이에 관한 
메커니즘을 다룬다. 본 실험은 프리온 단백질을 발현하지 않는 세포 
(HpL3-4)에 이가철 또는 삼가철을 노출한 후 재조합 프리온 
단백질을 외부에서 처리하였다. 이에 따라 세포로 유입되어 
존재하는 프리온의 양을 확인하여 보고 이의 생화학적 성질 변화를 
알아보기 위하여 proteinase K (PK) 분해에 대한 저항성과 
detergent 불용성을 살펴보았다. U18666A와 NH4Cl을 각각 
사용하여 소포성 운반과정과 소포-리소좀의 산성화를 저해해 
봄으로써 프리온 단백질 변성이 일어나는 과정을 유추하여보았다. 
실험을 통하여 이가철이 아닌 삼가철 특이적으로 세포 내 프리온 




처리 시간에 현격히 비례함을 확인할 수 있었다. 또한 이러한 
단백질의 축적은 galectin-3를 처리시 나타나지 않음을 통하여 
프리온 특이적인 반응인 것으로 판단할 수 있었다. 삼가철에 의해 
축적된 프리온 단백질은 detergent에 불용성을 띄었으며 PK 
분해에 저항성을 띄는 PrPres 이었다. 뿐만 아니라, 변성 프리온의 
생성은 U18666A에 의해서 저해되었으며 NH4Cl에 의한 영향은 
없었다. 이를 통하여 삼가철 매개의 변성 프리온 생성은 리소좀의 
산성환경이 아닌 소포성 운반 과정에서 형성된 것을 유추할 수 
있었다. 이제까지의 실험을 통하여 이가철 보다 삼가철이 프리온의 
변성에 관여하며 이러한 변성은 소포성의 운반과정에서 발생할 
것으로 보인다.   
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